CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight

The emerging pipeline of CAR-T in NHL includes late-stage, mid-stage, and early-stage drugs in different lines of therapies and different indications, mainly including B- cell Lymphoma such as DLBCL, FL, MCL, MZL, CLL/SLL, and others, with one of them being developed for a T-cell…